retatrutide parkinson clinical trial Parkinson's drug pipeline evolution and future directions | Michael S Okun posted on the topic Phase-3-Retatrutide-trial-sees-participants-achieve-up-to-30-weight-loss
Description
Slower escalation is gentler but delays peak results
B., Jacob J., Kao W
The FDA previously rejected Crexont in June 2023, citing insufficient safety data, as reported by Reuters
The weight-loss effect of glp-1ras glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: A systematic review with meta-analysis and trial sequential analysis of Randomized Controlled Trials
